Jacobs IA - Search Results

1

Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma.

Coleman M, Lammers PE, Ciceri F, Jacobs IA. Coleman M, et al. Among authors: jacobs ia. Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):175-81. doi: 10.1016/j.clml.2016.01.004. Epub 2016 Jan 30. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26906106 Free PMC article. Review.

2

Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.

Jackisch C, Lammers P, Jacobs I. Jackisch C, et al. Breast. 2017 Apr;32:199-216. doi: 10.1016/j.breast.2017.01.010. Epub 2017 Feb 23. Breast. 2017. PMID: 28236776 Free PMC article. Review.

3

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets.

Lammers P, Criscitiello C, Curigliano G, Jacobs I. Lammers P, et al. Pharmaceuticals (Basel). 2014 Sep 17;7(9):943-53. doi: 10.3390/ph7090943. Pharmaceuticals (Basel). 2014. PMID: 25232798 Free PMC article.

4

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.

Monk BJ, Lammers PE, Cartwright T, Jacobs I. Monk BJ, et al. Pharmaceuticals (Basel). 2017 Jan 28;10(1):19. doi: 10.3390/ph10010019. Pharmaceuticals (Basel). 2017. PMID: 28134851 Free PMC article.

5

Bispecific Antibodies in the Treatment of Hematologic Malignancies.

Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S. Duell J, et al. Clin Pharmacol Ther. 2019 Oct;106(4):781-791. doi: 10.1002/cpt.1396. Epub 2019 Mar 29. Clin Pharmacol Ther. 2019. PMID: 30770546 Free PMC article. Review.

6

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.

Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, Jacobs I. Lammers PE, et al. Br J Cancer. 2018 Aug;119(3):266-273. doi: 10.1038/s41416-018-0147-1. Epub 2018 Jul 13. Br J Cancer. 2018. PMID: 30002437 Free PMC article. Clinical Trial.

7

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.

Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P. Falchi L, et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29934061 Free article. Review.

8

Biosimilars and cancer treatment of older patients.

Lichtman SM, Reske T, Jacobs IA. Lichtman SM, et al. Among authors: jacobs ia. J Geriatr Oncol. 2016 Mar;7(1 Suppl):S1-8. doi: 10.1016/j.jgo.2016.01.002. Epub 2016 Feb 5. J Geriatr Oncol. 2016. PMID: 26856525 Free article.

9

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.

Rosen LS, Jacobs IA, Burkes RL. Rosen LS, et al. Among authors: jacobs ia. Target Oncol. 2017 Oct;12(5):599-610. doi: 10.1007/s11523-017-0518-1. Target Oncol. 2017. PMID: 28801849 Free PMC article. Review.

10

A clinician's guide to biosimilars in oncology.

Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. Rugo HS, et al. Cancer Treat Rev. 2016 May;46:73-9. doi: 10.1016/j.ctrv.2016.04.003. Epub 2016 Apr 21. Cancer Treat Rev. 2016. PMID: 27135548 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page